Patent intelligence · AU
AU 7517700
Solid lipid formulations
Solid lipid formulations
Patent details — AU 7517700
- Jurisdiction
- AU
- Status
- expired
- Grant date
- Apr 17, 2001
- Expiration
- Apr 12, 2021
- Applicant
- CHEPLAPHARM ARZNEIMITTEL GMBH
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 20 A I, A61K 9/ 46 A I, A61K 9/ 48 A I
Quick answer
AU 7517700 (Solid lipid formulations) is held by CHEPLAPHARM ARZNEIMITTEL GMBH. Status: expired. Granted Apr 17, 2001. Expires Apr 12, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CHEPLAPHARM ARZNEIMITTEL GMBH
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 20 A I, A61K 9/ 46 A I, A61K 9/ 48 A I, A61K 9/ 68 A I, A61K 31/ 365 A I
More from CHEPLAPHARM ARZNEIMITTEL GMBH
Related pharmaceutical patents in our USPTO index.
-
AU 2007332640
Powder formulation for valganciclovir
granted -
AU 2001289696
New use of lipase inhibitors
granted -
AU 2001289699
New pharmaceutical composition
expired -
AU 2002212120
Lipase inhibitors for the treatment of dyspepsia
expired -
AU 2001281846
Method for preparing a composition
expired -
AU 2002319189
Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof
expired -
AU 2002257817
Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
expired -
AU 2003222814
PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN
expired
Frequently asked questions
What is US patent 7517700?
AU 7517700 (Solid lipid formulations) is held by CHEPLAPHARM ARZNEIMITTEL GMBH. Status: expired. Granted Apr 17, 2001. Expires Apr 12, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 7517700?
CHEPLAPHARM ARZNEIMITTEL GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does AU 7517700 expire?
Our index shows an expiration date of Apr 12, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.